Related Experiment Video
Updated: May 6, 2026

Concurrent Electroencephalography Recording During Transcranial Alternating Current Stimulation tACS
Published on: January 22, 2016
Entacapone augmentation of antipsychotic treatment in schizophrenic patients with negative symptoms; a double-blind
Hanoch Kaphzan1, Dorit Ben-Shachar2, Ehud Klein2
1Sagol Department of Neurobiology, University of Haifa, Haifa, Israel.
Abstract:
Negative symptoms in schizophrenia are associated with decreased dopaminergic activity in the prefrontal cortex (PFC). It is hypothesized that increasing dopamine levels would alleviate negative symptoms. Termination of dopamine activity in the PFC is mainly via catechol-O-methyl tranferase (COMT) activity. Hence, inhibition of COMT activity with entacapone should reverse PFC dopaminergic transmission. To assess the efficacy of entacapone addition to antipsychotic treatment in patients with residual schizophrenia, we conducted a double-blind, randomised, placebo-controlled study for 12 wk of treatment with entacapone or placebo. Clinical measures (PANSS, CGI and QLS) were obtained at baseline and at weeks 4, 8 and 12 and cognitive functions were assessed by the RBANSS. Significant improvement over time in PANSS and QLS scores was observed in both groups. However, entacapone did not demonstrate a beneficial effect compared to placebo. Therefore, this study does not support a therapeutic role for entacapone in residual schizophrenia.
Related Concept Videos
Antipsychotic Drugs: Typical and Atypical Agents
Psychosis: Goals of Pharmacotherapy
Electroconvulsive Therapy
Antipsychotic Drugs: Therapeutic Uses and Side Effects
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Drug Therapy
Antianxiety Medications

